Founded in Suzhou in 2009, Kintor's product pipeline is built on proprietary R&D and licensing arrangements with a focus on prostate cancer, breast cancer, and liver cancer - which account for more than 50% of the global cancer population and lack effective treatment methods. The company aims to provide the best treatment plans for huge unmet patient needs by developing a full R&D and commercialization platform for "best-in-class" and "first-in-class" drugs. Kintor's drug candidate, Pruxelutamide, is currently undergoing phase III clinical trials in China and the United States for mCRPC and breast cancer, respectively. The company's pipeline includes seven drug candidates, including Pyrilutamide, Detorsertib, and Hedgehog/SMO Inhibitor, among others.